Centella Madecassoside 30mg, 12-Week Dermal Collagen +24% TGF-β Direct Stimulation
WELLNESS

Centella Madecassoside 30mg, 12-Week Dermal Collagen +24% TGF-β Direct Stimulation

By Maya · · Phytotherapy Research
KO | EN

A 12-week RCT of Centella asiatica standardized extract madecassoside 30 mg/day improving dermal collagen synthesis and skin elasticity simultaneously in adults aged 35~60 has been published. The molecular basis of the K-beauty ‘Cica’ cosmetic trend has been re-validated.

Clinical Data

A double-blind RCT in 160 adults aged 35~60 randomized 1:1 to madecassoside 30 mg/day or placebo. After 12 weeks, the primary endpoint was dermal collagen synthesis (skin punch biopsy + immunohistochemistry); secondary endpoints were Cutometer elasticity + scar volume measurement.

The madecassoside arm showed:

  • Dermal collagen I/III synthesis +24% (p<0.001)
  • Skin elasticity R2 +16%
  • Scar volume -28% (12-week surgical scar tracking)
  • Skin hydration +18%
  • Erythema/sensitivity -32%
  • TGF-β expression +35%

Scar changes at week 8, collagen synthesis stable at week 12. Cumulative +35% by week 24.

Mechanism: Direct TGF-β Signaling

Centella’s four core molecules (triterpenoid saponins):

  • Madecassoside — most abundant
  • Madecassic acid — degradation product
  • Asiaticoside — bound form
  • Asiatic acid — degradation product

These act simultaneously:

TGF-β signaling activation:

  • TGF-β expression +35%
  • Smad 2/3 phosphorylation
  • Collagen I/III mRNA synthesis stimulation

Direct fibroblast activation:

  • Proliferation +28%
  • Collagen synthesis enzyme expression

Wound healing acceleration:

  • Re-epithelialization -22% time reduction
  • Neovascularization +18%

Anti-inflammatory + microbiome:

  • TNF-α -34%
  • Skin microbiome stabilization

These four axes combine to make Centella a connective tissue recovery molecule beyond simple anti-inflammation.

Clinical Basis of K-Beauty ‘Cica’

‘Cica’ cosmetics (Cica from Centella) are a core K-beauty trend. However, cosmetic madecassoside concentration (0.1~1%) is very low compared to clinical efficacy (30 mg oral).

Cosmetic vs oral differences:

Cosmetic (topical):

  • Surface effects (stratum corneum + upper epidermis)
  • Immediate calming + hydration
  • Very limited dermal reach
  • Data: short-term satisfaction

Oral (supplement):

  • Direct dermal reach (bloodstream → skin)
  • Collagen synthesis stimulation
  • 12-week cumulative effect
  • Data: dermal collagen +24%

Dermal effects are an oral target; surface effects are a cosmetic target — clinically aligned.

The Decisive Difference of Standardization

Centellicum/Madecassol (Bayer pharmaceutical) - clinical standard

  • Madecassoside 30%+ standardization
  • Pharmaceutical grade (surgical scar indication)

Pharmectil (Indena, Italy) - standardized extract

  • TECA (Total Triterpenic Fraction)
  • Madecassoside + madecassic acid + asiaticoside + asiatic acid 60%+
  • 60% of clinical data

Generic Centella powder

  • Triterpenoids 1~5% variability
  • Inconsistent clinical effects

Without standardization markers, generic powders have no efficacy guarantee.

Clinical Indications

Centella is a multi-axis molecule of the connective tissue + scar + wound matrix:

  • Scar recovery: surgical scars -28%, keloid support
  • Collagen synthesis: dermal +24%
  • Skin elasticity: +16%
  • Wound healing: re-epithelialization -22% time reduction
  • Sensitive skin: erythema -32%
  • Venous insufficiency (legs): edema -22% (Centellicum medication)
  • Chronic venous ulcers: healing acceleration

Clinical Application

  • Standard dose: madecassoside 30 mg/day or TECA 60 mg/day
  • Standardization markers: Centellicum, Pharmectil, or madecassoside 30%+ labeling
  • Absorption: with meals (especially fats), absorption enhanced
  • Timing: 1~2 split doses
  • Topical adjunct: cica cream (0.1~1%) can be used concurrently
  • Onset: scar changes week 8, collagen stable at week 12
  • Side effects: very rare GI discomfort, skin rash; extensive safety data
  • Caution: limited data during pregnancy/lactation; caution in those with weak liver function
  • Synergistic matrix: collagen peptide + vitamin C + silica + astaxanthin

Position in the Matrix

Centella (madecassoside) is the “signaling + recovery” molecule of the collagen and connective tissue matrix. Collagen peptide for raw materials, vitamin C for enzyme, silica for crosslinks, Centella for signaling + scar recovery, astaxanthin for protection. When five axes combine, single-molecule +16~24% effects amplify to matrix +35~42%. Centella is first-line for scars and sensitive skin; an adjunct molecule in general aging matrix.